scholarly journals Genetic and Pathogenic Characterization of QX(GI-19)-Recombinant Infectious Bronchitis Viruses in South Korea

Viruses ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 1163
Author(s):  
So-Youn Youn ◽  
Ji-Youn Lee ◽  
You-Chan Bae ◽  
Yong-Kuk Kwon ◽  
Hye-Ryoung Kim

Infectious bronchitis viruses (IBVs) are evolving continuously via genetic drift and genetic recombination, making disease prevention and control difficult. In this study, we undertook genetic and pathogenic characterization of recombinant IBVs isolated from chickens in South Korea between 2003 and 2019. Phylogenetic analysis showed that 46 IBV isolates belonged to GI-19, which includes nephropathogenic IBVs. Ten isolates formed a new cluster, the genomic sequences of which were different from those of reference sequences. Recombination events in the S1 gene were identified, with putative parental strains identified as QX-like, KM91-like, and GI-15. Recombination detection methods identified three patterns (rGI-19-I, rGI-19-II, and rGI-19-III). To better understand the pathogenicity of recombinant IBVs, we compared the pathogenicity of GI-19 with that of the rGI-19s. The results suggest that rGI-19s may be more likely to cause trachea infections than GI-19, whereas rGI-19s were less pathogenic in the kidney. Additionally, the pathogenicity of rGI-19s varied according to the genotype of the major parent. These results indicate that genetic recombination between heterologous strains belonging to different genotypes has occurred, resulting in the emergence of new recombinant IBVs in South Korea.

2015 ◽  
Vol 122 (1-2) ◽  
pp. 195-204 ◽  
Author(s):  
T. Yatabe ◽  
S.J. More ◽  
F. Geoghegan ◽  
C. McManus ◽  
A.E. Hill ◽  
...  

Viruses ◽  
2020 ◽  
Vol 12 (12) ◽  
pp. 1389 ◽  
Author(s):  
Sol Jeong ◽  
Dong-Hun Lee ◽  
Jung-Hoon Kwon ◽  
Yu-Jin Kim ◽  
Sun-Hak Lee ◽  
...  

In October 2020, a highly pathogenic avian influenza (HPAI) subtype H5N8 virus was identified from a fecal sample of a wild mandarin duck (Aix galericulata) in South Korea. We sequenced all eight genome segments of the virus, designated as A/Mandarin duck/Korea/K20-551-4/2020(H5N8), and conducted genetic characterization and comparative phylogenetic analysis to track its origin. Genome sequencing and phylogenetic analysis show that the hemagglutinin gene belongs to H5 clade 2.3.4.4 subgroup B. All genes share high levels of nucleotide identity with H5N8 HPAI viruses identified from Europe during early 2020. Enhanced active surveillance in wild and domestic birds is needed to monitor the introduction and spread of HPAI via wild birds and to inform the design of improved prevention and control strategies.


Viruses ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 1045
Author(s):  
Hyuk-Chae Lee ◽  
Sol Jeong ◽  
Andrew Y. Cho ◽  
Kyu-Jik Kim ◽  
Jun-Young Kim ◽  
...  

Infectious bronchitis virus (IBV) was first identified in the 1930s and it imposes a major economic burden on the poultry industry. In particular, GI-19 lineage has spread globally and has evolved constantly since it was first detected in China. In this study, we analyzed S1 gene sequences from 60 IBVs isolated in South Korea. Two IBV lineages, GI-15 and GI-19, were identified in South Korea. Phylogenetic analysis suggested that there were six distinct subgroups (KM91-like, K40/09-like, and QX-like I to IV) of the South Korean GI-19 IBVs. Among them, QX-type III and IV subgroups, which are phylogenetically different from those reported in South Korea in the past, accounted for more than half of the total. Moreover, the phylogeographic analysis of the QX-like subgroups indicated at least four distinct introductions of GI-19 IBVs into South Korea during 2001–2020. The efficacy of commercialized vaccines against the recently introduced QX-like subgroups should be verified, and continuous international surveillance efforts and quarantine procedures should be enhanced to prevent the incursion of viruses.


Author(s):  
Yun-Jung Kang

Abstract As of 25 July 2021, the Korea Disease Control and Prevention Agency reported 1,422 new COVID-19 cases, 188,848 total cases, and 2.073 total deaths (1.10% fatality rates). Since the first SARS-CoV-2 case was reported, efforts to find a treatment and vaccine against COVID-19 have been widespread. Four vaccines are on the WHO’s emergency use listing and are approved of their usage; BNT162b2, mRNA-1273, AZD1222, and Ad26.COV2.S. Vaccines against SARS-CoV-2 need at least 14 days to achieve effectiveness. Thus, people should abide by prevention and control measures, including wearing masks, washing hands, and social distancing. However, a lot of new cases were reported after vaccinations, as many people did not follow the prevention control measures before the end of the 14 days period. There is no doubt we need to break free from mask mandates. But let us not decide the timing in haste. Even if the mask mandates are eased, they should be changed depending on the number of reported cases, vaccinations, as well as prevention and control measures on how circumstances are changing under the influence of mutant coronavirus.


2017 ◽  
Vol 27 (2) ◽  
pp. 131-138 ◽  
Author(s):  
Magda Osman ◽  
Amanda J. Heath ◽  
Ragnar Löfstedt

Public regulators (such as European Food Safety Authority, European Medicines Agency, and European Centre for Disease Prevention and Control) are placing increasing demands on scientists to make uncertainties about their evidence transparent to the public. The stated goal is utilitarian, to inform and empower the public and ensure the accountability of policy and decision-making around the use of scientific evidence. However, it is questionable what constitutes uncertainty around the evidence on any given topic, and, while the goal is laudable, we argue the drive to increase transparency on uncertainty of the scientific process specifically does more harm than good, and may not serve the interests of those intended. While highlighting some of the practical implications of making uncertainties transparent using current guidelines, the aim is to discuss what could be done to make it worthwhile for both public and scientists.


2004 ◽  
Vol 8 (40) ◽  
Author(s):  

A startup event was held for the new European Union agency, the European Centre for Disease Prevention and Control, in Stockholm on 27 September, in preparation for the operational start date of May 2005


2005 ◽  
Vol 10 (39) ◽  
Author(s):  

A further position is being advertised at the European Centre for Disease Prevention and Control (ECDC) in Stockholm.


Sign in / Sign up

Export Citation Format

Share Document